Kidney Transplantation-Pipeline Review, H2 2015

Kidney Transplantation-Pipeline Review, H2 2015

  • Products Id :- GMDHC7291IDB
  • |
  • Pages: 159
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Kidney Transplantation-Pipeline Review, H2 2015


Global Markets Direct's, 'Kidney transplantation-Pipeline Review, H2 2015', provides an overview of the Kidney transplantation's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Kidney transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney transplantation and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Kidney transplantation

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Kidney transplantation and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Kidney transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Kidney transplantation pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Kidney transplantation

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Kidney transplantation pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Kidney Transplantation Overview 10

Therapeutics Development 11

Pipeline Products for Kidney Transplantation-Overview 11

Pipeline Products for Kidney Transplantation-Comparative Analysis 12

Kidney Transplantation-Therapeutics under Development by Companies 13

Kidney Transplantation-Therapeutics under Investigation by Universities/Institutes 15

Kidney Transplantation-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Unknown Stage Products 19

Kidney Transplantation-Products under Development by Companies 20

Kidney Transplantation-Products under Investigation by Universities/Institutes 22

Kidney Transplantation-Companies Involved in Therapeutics Development 23

Alexion Pharmaceuticals, Inc. 23

Amyndas Pharmaceuticals LLC 24

Angion Biomedica Corp. 25

Astellas Pharma Inc. 26

Bio-inRen 27

Catalyst Biosciences, Inc. 28

CSL Limited 29

Digna Biotech, S.L. 30

Dompe Farmaceutici S.p.A. 31

Effimune SAS 32

GlaxoSmithKline Plc 33

Grifols, S.A. 34

Hansa Medical AB 35

Kyowa Hakko Kirin Co., Ltd. 36

Mabtech Limited 37

Novartis AG 38

Onyx Pharmaceuticals, Inc. 39

Opsona Therapeutics Limited 40

Pharming Group N.V. 41

Prolong Pharmaceuticals 42

Quark Pharmaceuticals, Inc. 43

Shire Plc 44

t-cell Europe GmbH 45

Tiziana Life Sciences Plc 46

Zyrnat Biotherapeutics SL 47

Kidney Transplantation-Therapeutics Assessment 48

Assessment by Monotherapy Products 48

Assessment by Target 49

Assessment by Mechanism of Action 51

Assessment by Route of Administration 53

Assessment by Molecule Type 55

Drug Profiles 57

albumin (human)-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

AMY-101-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

AS-2521780-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

basiliximab biobetter-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

BB-3-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

belimumab-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

bleselumab-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

BRN-1889-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

C1 esterase inhibitor (human)-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

C1 esterase inhibitor (human)-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

C1 esterase inhibitor (human)-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

Cardiotrophin-1-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

carfilzomib-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

CB-2782-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

Cell Therapy for Kidney Transplantation-Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

Cell Therapy for Kidney Transplantation-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

CFZ-533-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

Dendritic Cell Therapy for Multiple Sclerosis and Kidney Transplantation-Drug Profile 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

eculizumab-Drug Profile 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

EFFI-7H-Drug Profile 95

Product Description 95

Mechanism of Action 95

R&D Progress 95

ETR-002-Drug Profile 96

Product Description 96

Mechanism of Action 96

R&D Progress 96

FCR-001-Drug Profile 97

Product Description 97

Mechanism of Action 97

R&D Progress 97

foralumab-Drug Profile 99

Product Description 99

Mechanism of Action 99

R&D Progress 99

FR-104-Drug Profile 100

Product Description 100

Mechanism of Action 100

R&D Progress 100

FX-06-Drug Profile 102

Product Description 102

Mechanism of Action 102

R&D Progress 102

Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation, Cardiovascular Disease and Oncology-Drug Profile 104

Product Description 104

Mechanism of Action 104

R&D Progress 104

OPN-305-Drug Profile 106

Product Description 106

Mechanism of Action 106

R&D Progress 106

QPI-1002-Drug Profile 108

Product Description 108

Mechanism of Action 108

R&D Progress 108

Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation-Drug Profile 110

Product Description 110

Mechanism of Action 110

R&D Progress 110

reparixin-Drug Profile 112

Product Description 112

Mechanism of Action 112

R&D Progress 112

Sanguinate-Drug Profile 114

Product Description 114

Mechanism of Action 114

R&D Progress 114

T-Cell Therapy for Kidney Transplant-Drug Profile 116

Product Description 116

Mechanism of Action 116

R&D Progress 116

ZY-11-Drug Profile 117

Product Description 117

Mechanism of Action 117

R&D Progress 117

Kidney Transplantation-Recent Pipeline Updates 118

Kidney Transplantation-Dormant Projects 150

Kidney Transplantation-Dormant Projects 150

Kidney Transplantation-Discontinued Products 151

Kidney Transplantation-Product Development Milestones 152

Featured News & Press Releases 152

Oct 13, 2015: Shire's CINRYZE (C1 esterase inhibitor [human]) Receives FDA Fast Track Designation for Investigation in the Treatment of Antibody Mediated Rejection in Patients Receiving Kidney Transplants 152

Sep 15, 2015: Data from Hansa Medical's First Phase II study of IdeS in Sensitized Kidney Transplantation Patients Presented in Oral Session at ESOT 2015 152

Sep 14, 2015: Hansa Medical receives FDA Orphan Drug Designation for IdeS 153

Aug 11, 2015: First patient in IdeS study at Cedars-Sinai Medical Center in Los Angeles receives kidney transplantation 153

Jul 22, 2015: TRACT Therapeutics Completes Phase I Safety Trial Using a Patient's Immune Cells to Prevent Organ Rejection 154

Jul 09, 2015: Effimune launches Phase I clinical trial on immune system regulation control 154

May 14, 2015: Angion Biomedica Advances BB3 into Pivotal Phase 3 Clinical Trial in Renal Transplant Patients with Delayed Graft Function 155

May 06, 2015: Hansa Medical Establishes a US medical advisory board for IdeS in kidney transplantation 156

Apr 13, 2015: Alexion Announces Presentations at 2015 American Transplant Congress, Including Results from Studies Advancing the Understanding of Eculizumab (Soliris) in Patients Undergoing Kidney Transplant 156

Feb 12, 2015: Hansa Medical develops second-generation IdeS molecules for repeat dosing 157

Appendix 158

Methodology 158

Coverage 158

Secondary Research 158

Primary Research 158

Expert Panel Validation 158

Contact Us 158

Disclaimer 15

List of Tables

Number of Products under Development for Kidney Transplantation, H2 2015 11

Number of Products under Development for Kidney Transplantation-Comparative Analysis, H2 2015 12

Number of Products under Development by Companies, H2 2015 13

Number of Products under Investigation by Universities/Institutes, H2 2015 15

Comparative Analysis by Late Stage Development, H2 2015 16

Comparative Analysis by Clinical Stage Development, H2 2015 17

Comparative Analysis by Early Stage Development, H2 2015 18

Comparative Analysis by Unknown Stage Development, H2 2015 19

Products under Development by Companies, H2 2015 20

Products under Development by Companies, H2 2015 (Contd..1) 21

Products under Investigation by Universities/Institutes, H2 2015 22

Kidney Transplantation-Pipeline by Alexion Pharmaceuticals, Inc., H2 2015 23

Kidney Transplantation-Pipeline by Amyndas Pharmaceuticals LLC, H2 2015 24

Kidney Transplantation-Pipeline by Angion Biomedica Corp., H2 2015 25

Kidney Transplantation-Pipeline by Astellas Pharma Inc., H2 2015 26

Kidney Transplantation-Pipeline by Bio-inRen, H2 2015 27

Kidney Transplantation-Pipeline by Catalyst Biosciences, Inc., H2 2015 28

Kidney Transplantation-Pipeline by CSL Limited, H2 2015 29

Kidney Transplantation-Pipeline by Digna Biotech, S.L., H2 2015 30

Kidney Transplantation-Pipeline by Dompe Farmaceutici S.p.A., H2 2015 31

Kidney Transplantation-Pipeline by Effimune SAS, H2 2015 32

Kidney Transplantation-Pipeline by GlaxoSmithKline Plc, H2 2015 33

Kidney Transplantation-Pipeline by Grifols, S.A., H2 2015 34

Kidney Transplantation-Pipeline by Hansa Medical AB, H2 2015 35

Kidney Transplantation-Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015 36

Kidney Transplantation-Pipeline by Mabtech Limited, H2 2015 37

Kidney Transplantation-Pipeline by Novartis AG, H2 2015 38

Kidney Transplantation-Pipeline by Onyx Pharmaceuticals, Inc., H2 2015 39

Kidney Transplantation-Pipeline by Opsona Therapeutics Limited, H2 2015 40

Kidney Transplantation-Pipeline by Pharming Group N.V., H2 2015 41

Kidney Transplantation-Pipeline by Prolong Pharmaceuticals, H2 2015 42

Kidney Transplantation-Pipeline by Quark Pharmaceuticals, Inc., H2 2015 43

Kidney Transplantation-Pipeline by Shire Plc, H2 2015 44

Kidney Transplantation-Pipeline by t-cell Europe GmbH, H2 2015 45

Kidney Transplantation-Pipeline by Tiziana Life Sciences Plc, H2 2015 46

Kidney Transplantation-Pipeline by Zyrnat Biotherapeutics SL, H2 2015 47

Assessment by Monotherapy Products, H2 2015 48

Number of Products by Stage and Target, H2 2015 50

Number of Products by Stage and Mechanism of Action, H2 2015 52

Number of Products by Stage and Route of Administration, H2 2015 54

Number of Products by Stage and Molecule Type, H2 2015 56

Kidney Transplantation Therapeutics-Recent Pipeline Updates, H2 2015 118

Kidney Transplantation-Dormant Projects, H2 2015 150

Kidney Transplantation-Discontinued Products, H2 2015 151

List of Figures

Number of Products under Development for Kidney Transplantation, H2 2015 11

Number of Products under Development for Kidney Transplantation-Comparative Analysis, H2 2015 12

Number of Products under Development by Companies, H2 2015 13

Comparative Analysis by Clinical Stage Development, H2 2015 17

Comparative Analysis by Early Stage Products, H2 2015 18

Assessment by Monotherapy Products, H2 2015 48

Number of Products by Top 10 Targets, H2 2015 49

Number of Products by Stage and Top 10 Targets, H2 2015 49

Number of Products by Top 10 Mechanism of Actions, H2 2015 51

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 51

Number of Products by Routes of Administration, H2 2015 53

Number of Products by Stage and Routes of Administration, H2 2015 53

Number of Products by Molecule Types, H2 2015 55

Number of Products by Stage and Molecule Types, H2 2015 55

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Alexion Pharmaceuticals, Inc.

Amyndas Pharmaceuticals LLC

Angion Biomedica Corp.

Astellas Pharma Inc.


Catalyst Biosciences, Inc.

CSL Limited

Digna Biotech, S.L.

Dompe Farmaceutici S.p.A.

Effimune SAS

GlaxoSmithKline Plc

Grifols, S.A.

Hansa Medical AB

Kyowa Hakko Kirin Co., Ltd.

Mabtech Limited

Novartis AG

Onyx Pharmaceuticals, Inc.

Opsona Therapeutics Limited

Pharming Group N.V.

Prolong Pharmaceuticals

Quark Pharmaceuticals, Inc.

Shire Plc

t-cell Europe GmbH

Tiziana Life Sciences Plc

Zyrnat Biotherapeutics SL

Kidney transplantation Therapeutic Products under Development, Key Players in Kidney transplantation Therapeutics, Kidney transplantation Pipeline Overview, Kidney transplantation Pipeline, Kidney transplantation Pipeline Assessment

select a license

Single User License
USD 2000 INR 134900
Site License
USD 4000 INR 269800
Corporate User License
USD 6000 INR 404700



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]